Literature DB >> 26886714

Rituximab-refractory lupus nephritis successfully treated with belimumab.

Cristina Gonzalez-Echavarri1, Amaia Ugarte2, Guillermo Ruiz-Irastorza2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26886714

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN： 0392-856X            Impact factor:   4.473


× No keyword cloud information.
  11 in total

Review 1.  B Cell-Based Treatments in SLE: Past Experience and Current Directions.

Authors:  Stamatis-Nick C Liossis; Chrysanthi Staveri
Journal:  Curr Rheumatol Rep       Date:  2017-11-04       Impact factor: 4.592

Review 2.  New Trials in Lupus and where Are we Going.

Authors:  Aikaterini Thanou; Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2018-05-03       Impact factor: 4.592

Review 3.  Belimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: case series and literature review.

Authors:  Domenico Paolo Emanuele Margiotta; Fabio Basta; Veronica Batani; Antonella Afeltra
Journal:  BMC Nephrol       Date:  2018-03-07       Impact factor: 2.388

Review 4.  Novel Treatments in Lupus.

Authors:  Milena Vukelic; Yi Li; Vasileios C Kyttaris
Journal:  Front Immunol       Date:  2018-11-16       Impact factor: 7.561

5.  Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.

Authors:  Y K Onno Teng; Ian N Bruce; Betty Diamond; Richard A Furie; Ronald F van Vollenhoven; David Gordon; James Groark; Robert B Henderson; Mary Oldham; Paul P Tak
Journal:  BMJ Open       Date:  2019-03-20       Impact factor: 2.692

Review 6.  Individualizing Therapy in Lupus Nephritis.

Authors:  Yu An; Haitao Zhang; Zhihong Liu
Journal:  Kidney Int Rep       Date:  2019-08-20

7.  Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results.

Authors:  Tineke Kraaij; Eline J Arends; Laura S van Dam; Sylvia W A Kamerling; Paul L A van Daele; Obbo W Bredewold; Argho Ray; Jaap A Bakker; Hans U Scherer; Tom J W Huizinga; Ton J Rabelink; Cees van Kooten; Y K Onno Teng
Journal:  Nephrol Dial Transplant       Date:  2021-07-23       Impact factor: 5.992

Review 8.  Use of belimumab in real-world in Spain: a scoping review about characteristics of SLE patients.

Authors:  Carlos Rodríguez Escalera; Ángela María Zurita Guisado; Francisco Javier Mateo; Noemí Bahamontes-Rosa; María Jesús García Villanueva
Journal:  Clin Rheumatol       Date:  2022-07-23       Impact factor: 3.650

9.  Clinical Efficacy of Routinely Administered Belimumab on Proteinuria and Neuropsychiatric Lupus.

Authors:  Marlene Plüß; Björn Tampe; Noah Niebusch; Michael Zeisberg; Gerhard A Müller; Peter Korsten
Journal:  Front Med (Lausanne)       Date:  2020-05-27

10.  Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies.

Authors:  Luca Petricca; Maria Rita Gigante; Annamaria Paglionico; Stefano Costanzi; Gisella Vischini; Clara Di Mario; Valentina Varriano; Giacomo Tanti; Barbara Tolusso; Stefano Alivernini; Giuseppe Grandaliano; Gianfranco Ferraccioli; Elisa Gremese
Journal:  Front Med (Lausanne)       Date:  2020-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.